Umed Clinical Trials Sp. z o.o.
- Address
- Bud A-2, Ul. Pomorska 251, 92-213 Lodz, Poland
Umed Clinical Trials - Advanced Metabolic, Cardiovascular & Immunological Research
Umed Clinical Trials Sp. z o.o. is a specialized clinical research center with extensive expertise in conducting complex therapeutic trials across multiple disease areas. The facility demonstrates particular strength in metabolic disorders, cardiovascular conditions, and autoimmune diseases, participating in cutting-edge Phase 2 and Phase 3 studies that advance treatment paradigms for both adult and pediatric populations.
- Cardiovascular Research: Heart failure with preserved and reduced ejection fraction (HFpEF/HFrEF), hypertrophic cardiomyopathy, and acute decompensated heart failure trials
- Metabolic & Endocrine Disorders: Type 1 diabetes prevention and treatment, obesity management in adolescents, and diabetes autoimmunity studies
- Autoimmune & Immunological Conditions: Primary Sjögren's disease, lupus nephritis, IgA nephropathy, and hereditary angioedema
- Oncology: Non-small cell lung cancer immunotherapy trials combining novel checkpoint inhibitors
The center has established significant capabilities in pediatric and adolescent research, conducting studies in populations ranging from infants to young adults. Their portfolio includes innovative trials investigating disease-modifying therapies, novel immunomodulatory agents, and preventive interventions for chronic conditions. Umed Clinical Trials demonstrates commitment to advancing precision medicine approaches, particularly in areas of high unmet medical need where new therapeutic options can significantly impact patient outcomes and quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 15 of 29 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
- 1Adarx Pharmaceuticals Inc.2active
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Adarx Pharmaceuticals Inc.2trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Umed Clinical Trials Sp. z o.o.
lock Showing 1 of 28 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy | Sanofi-Aventis Recherche & Developpement | Phase II | Not Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 29 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| ADX-324 | 2 | Unknown | 2026-01-16 | 2026-01-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.